Methods for treatment of cardiovascular disease
This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
1. A method for treating a subject to reduce the risk of developing a cardiovascular condition, the method comprising:
determining a level of secreted ST2 in a biological sample from a subject at risk of developing a cardiovascular condition;
comparing the level of secreted ST2 in the biological sample to a control;
identifying the subject having an elevated level of secreted ST2 relative to a control; and
administering to the identified subject an agent that reduces the risk of the cardiovascular condition.
2. The method of claim 1 , wherein the cardiovascular condition is characterized by mechanical strain, mechanical overload, or mechanically-induced deformation in cardiac cells or tissue.
3. The method of claim 1 , wherein the cardiovascular condition is selected from the group consisting of: cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
4. The method of claim 1 , wherein the biological sample is blood or serum.
5. The method of claim 1 , wherein the determining is performed using an antibody or an antibody fragment that binds to secreted ST2.
6. The method of claim 5 , wherein the antibody or antibody fragment is labeled with a radioactive label or an enzyme.
7. The method of claim 1 , wherein the subject is a human.
8. The method of claim 1 , wherein the control is a predetermined level.
9. The method of claim 1 , wherein the control is a level of secreted ST2 in a healthy subject.
10. The method of claim 1 , wherein the subject is hypercholesterolemic, hypertriglyceridemic, hyperlidemic, a smoker, or hypertensive.
11. The method of claim 1 , wherein the agent is selected from the group consisting of: an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid-reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, and renin-angiotensin system (RAS) inhibitors.
12. The method of claim 11 , wherein the renin-angiotensin system inhibitor is selected from the group consisting of: an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), an angiotensin II receptor antagonist, an agent that activates the catabolism of angiotensin II, and an agent that prevents the synthesis of angiotensin I.
13. The method of claim 1 , wherein the agent is administered orally, rectally, topically, nasally, intradermally, transdermally, by infusion, intravenously, or intramuscularly.
14. The method of claim 1 , wherein the agent is formulated for timed-release, delayed-release, or sustained-release.